Viking Therapeutics, Inc.
VKTX
$34.42
$0.922.75%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 14.42M | 14.08M | 15.25M | 13.77M | 10.29M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 74.57M | 55.47M | 46.24M | 36.56M | 34.05M |
Operating Income | -74.57M | -55.47M | -46.24M | -36.56M | -34.05M |
Income Before Tax | -65.56M | -45.63M | -35.42M | -24.94M | -22.25M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -65.56M | -45.63M | -35.42M | -24.94M | -22.25M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -65.56M | -45.63M | -35.42M | -24.94M | -22.25M |
EBIT | -74.57M | -55.47M | -46.24M | -36.56M | -34.05M |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | -0.58 | -0.41 | -0.32 | -0.22 | -0.20 |
Normalized Basic EPS | -0.37 | -0.25 | -0.20 | -0.14 | -0.13 |
EPS Diluted | -0.58 | -0.41 | -0.32 | -0.22 | -0.20 |
Normalized Diluted EPS | -0.37 | -0.25 | -0.20 | -0.14 | -0.13 |
Average Basic Shares Outstanding | 112.13M | 112.07M | 111.34M | 110.91M | 110.39M |
Average Diluted Shares Outstanding | 112.13M | 112.07M | 111.34M | 110.91M | 110.39M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |